<DOC>
	<DOCNO>NCT00995722</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability prednisone patient diagnose ocular myasthenia . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Efficacy Prednisone In Treatment Ocular Myasthenia</brief_title>
	<detailed_description>The purpose study learn two thing prednisone patient ocular myasthenia . The first thing aim learn whether prednisone effective improving symptom double vision droop eye experience patient ocular myasthenia . The second thing aim learn whether find dose prednisone well tolerate safe . The overall goal find whether dose prednisone safe well tolerate also effective improve symptom ocular myasthenia . After complete screen assessment confirm eligibility , participant receive treatment pyridostigmine . If participant 's symptom resolve within first month treat pyridostigmine , randomize receive prednisone placebo . The amount study medication participant receive depend symptom respond medication experience side effect . After four month , participant continue symptom ocular myasthenia side effect receive open label high dose prednisone . Participants longer symptom taper dose study drug double-blind fashion .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Pyridostigmine Bromide</mesh_term>
	<criteria>Weakness confine extraocular muscle , eyelid levator eye closure ocularQMG1 score â‰¥ 1 At least one follow combination abnormal diagnostic testing : ) Elevated acetylcholine receptor antibody titer , ( b ) Abnormal repetitive nerve stimulation ( &gt; 10 % decrement follow slow repetitive nerve stimulation ) nervemuscle pair , ( c ) Abnormal jitter single fiber concentric needle electromyography muscle , ( ) Positive ice test brain MRI demonstrate central nervous system pathology mimic ocular myasthenia , ( e ) Positive Tensilon test brain MRI demonstrate central nervous system pathology mimic ocular myasthenia Either prior treatment pyridostigmine , participant persistent ocular symptom functionally limit troublesome despite treatment pyridostigmine . Age 18 year old , male female Capable providing inform consent comply study procedure Identifiable primary care physician assist management medical complication may arise consequence steroid therapy Willing randomize trial prednisone placebo symptom respond inadequately pyridostigmine . Disease duration ( time since symptom onset ) &gt; 5 year Treatment prednisone corticosteroid within 90 day randomization Treatment azathioprine , cyclosporine , mycophenolate mofetil immune suppressive medication since onset MG unless dosage medication and/or duration therapy medication clinically insignificant judgment PI Intravenous immunoglobulin plasma exchange within 90 day randomization Prior thymectomy history thymoma Contraindication steroid ( poorly control diabetes , glaucoma hypertension , history prior steroid intolerance , obesity [ BMI &gt; 39.9kg/m2 ] history osteoporotic fracture ) Pregnant lactate Renal failure , active thyroid hepatocellular disease , chronic infection , poorly control cardiac disease , unstable psychiatric illness , untreated major depression illness would , opinion treat neurologist , make unsafe patient participate trial Receipt another investigational drug within 30 day Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Ocular myasthenia gravis</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Steroids</keyword>
</DOC>